Physician profile
Suong Tran
NPI 1851591978
$18,205.64
in general payments reported to CMS, 2019-2025
26 companies · $2,391 in 2025
The $2,391 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,875 · 2020: $2,906 · 2021: $1,945 · 2022: $1,887 · 2023: $2,310 · 2024: $2,892 · 2025: $2,391.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,274 · Education: $319.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,274.28 |
| Education | $319.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $6,102.34 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Amgen INC. | $3,103.88 | 2019-2025 | Enbrel, Tavneos, Otezla |
| Ucb, INC. | $1,273.77 | 2019-2025 | Cimzia, Bimzelx |
| Janssen Biotech, INC. | $1,268.48 | 2019-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $1,223.34 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,142.97 | 2019-2025 | Orencia |
| Horizon Therapeutics Plc | $1,100.23 | 2019-2022 | |
| Genzyme Corporation | $393.58 | 2019-2024 | |
| Aurinia Pharma U.S., INC. | $363.72 | 2022-2024 | Lupkynis |
| Pfizer INC. | $355.70 | 2019-2024 | |
| Lilly USA, LLC | $302.70 | 2019-2023 | Taltz |
| Mallinckrodt Enterprises LLC | $236.78 | 2019 | |
| Genentech USA, INC. | $230.31 | 2019-2024 | Actemra |
| Glaxosmithkline, LLC. | $196.98 | 2019-2025 | Benlysta |
| Mallinckrodt Hospital Products INC. | $193.56 | 2020-2023 | Acthar |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $161.64 | 2021-2024 | Saphnelo |
| Celgene Corporation | $132.19 | 2019 | |
| Sanofi-Aventis U.S. LLC | $119.48 | 2019 | |
| Tersera Therapeutics LLC | $73.98 | 2022-2023 | Quzyttir |
| Medexus Pharma, INC. | $66.76 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.67 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $38.79 | 2019-2025 | Keytruda Qlex, Keytruda |
| Sobi, INC | $25.49 | 2024 | |
| Radius Health, INC. | $19.80 | 2019 | |
| Sandoz INC. | $15.63 | 2024 | Hyrimoz |
| Hikma Pharmaceuticals USA | $14.87 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suong Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.